Walmart, U.S. pharmacy chains cap COVID-19 test sales amid Omicron surge
Reuters
Published Dec 21, 2021 03:20PM ET
Updated Dec 21, 2021 04:16PM ET
(Reuters) -Walmart Inc, Walgreens Boots Alliance (NASDAQ:WBA) and CVS Health Corp (NYSE:CVS) have limited sales of at-home COVID-19 testing kits as demand surges due to the rapid spread of the Omicron variant of the coronavirus.
The variant has become dominant in the United States with lightning speed, dashing hopes for a more normal holiday season, resurrecting restrictions and stretching the country's testing infrastructure ahead of holiday travel and gatherings.
Walgreens said in an emailed statement on Tuesday that it would limit both online and in-store purchases of test kits to four per customer. The company also said it was working with suppliers to catch up with demand.
Walmart (NYSE:WMT) set a limit of eight tests for each online order, but allowed its physical stores to set their own limits depending on inventory levels.
"We do have strong inventory levels nationally in store," Walmart said in a statement. "However, inventory is more limited online depending on the zip code."
CVS limited sales of test kits to six per person and said the products might be temporarily out of stock on its website as it priorities inventories at its stores.
The Biden administration said earlier in the day it would buy 500 million at-home rapid tests that Americans can order online for free starting in January.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.